Cargando…
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543833/ https://www.ncbi.nlm.nih.gov/pubmed/35604243 http://dx.doi.org/10.1002/ajh.26618 |
| _version_ | 1784804465714397184 |
|---|---|
| author | Gambacorti‐Passerini, Carlo Nicolini, Franck Emmanuel Larson, Richard A. Aroldi, Andrea Fontana, Diletta Piazza, Rocco le Coutre, Philipp Antolini, Laura Assouline, Sarit |
| author_facet | Gambacorti‐Passerini, Carlo Nicolini, Franck Emmanuel Larson, Richard A. Aroldi, Andrea Fontana, Diletta Piazza, Rocco le Coutre, Philipp Antolini, Laura Assouline, Sarit |
| author_sort | Gambacorti‐Passerini, Carlo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9543833 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95438332022-10-14 Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia Gambacorti‐Passerini, Carlo Nicolini, Franck Emmanuel Larson, Richard A. Aroldi, Andrea Fontana, Diletta Piazza, Rocco le Coutre, Philipp Antolini, Laura Assouline, Sarit Am J Hematol Correspondences John Wiley & Sons, Inc. 2022-06-09 2022-08 /pmc/articles/PMC9543833/ /pubmed/35604243 http://dx.doi.org/10.1002/ajh.26618 Text en © 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correspondences Gambacorti‐Passerini, Carlo Nicolini, Franck Emmanuel Larson, Richard A. Aroldi, Andrea Fontana, Diletta Piazza, Rocco le Coutre, Philipp Antolini, Laura Assouline, Sarit Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title | Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title_full | Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title_fullStr | Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title_full_unstemmed | Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title_short | Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| title_sort | caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia |
| topic | Correspondences |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543833/ https://www.ncbi.nlm.nih.gov/pubmed/35604243 http://dx.doi.org/10.1002/ajh.26618 |
| work_keys_str_mv | AT gambacortipasserinicarlo cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT nicolinifranckemmanuel cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT larsonricharda cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT aroldiandrea cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT fontanadiletta cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT piazzarocco cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT lecoutrephilipp cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT antolinilaura cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia AT assoulinesarit cautioninusingsecondgenerationtyrosinekinaseinhibitorespeciallyforfirstlinetherapyofchronicmyeloidleukemia |